Click to Share
 

Gene Therapy Press Releases

+ Alert
+ Feed
Exclusive News
Topics Locations Industries Dates

12654663
By Project Alive
Parents Trying to Help Fund a Cure For the Rare Disease Hunter Syndrome / MPS II
12648948
By Project Alive
Parent Efforts Bringing Awareness to the Rare Disease Hunter Syndrome / MPS II
12641592
By Aldevron
Henry Hebel has been named Chief Operating Officer of Aldevron, a leading global provider of contract plasmid DNA manufacturing, protein production and antibody discovery services.
By Boston Biotech Meetup
Join the Boston Biotech Meetup for Advances in Gene Therapy, an evening of networking, presentations and discussion with local scientists.
12619832
By FAST
A pioneer on the frontier of genetic medicine and his team at one of the nation's top-five medical research schools have joined forces with FAST (Foundation for Angelman Syndrome Therapeutics) to develop a treatment for the rare disorder Angelman...
12597830
By Saving Case & Friends, Inc.
Parent-led fundraising efforts have donated over $500,000 to treat the rare disease Hunter Syndrome (MPS II)
12588923
By MoBiTec GmbH
AUMsilence self-delivering oligos achieve highly efficient and potent antisense-based gene knockdown. No need to use toxic transfection reagents. Especially designed for primary cells and very difficult-to-transfect cell types.
12554233
By Saving Case & Friends, Inc.
Efforts Bringing Awareness to Hunter Syndrome Are Recognized by Telly Awards and International Songwriting Competition
12474216
By Project Alive, a campaign of Saving Case & Friends
Parents of children with the rare disease Hunter Syndrome launched a compelling awareness and fundraising campaign with celebrity support including Seattle Seahawks head coach Pete Carroll and radio host Dave Ramsey.
By Cure SMA
Cure SMA, the leading organization dedicated to the treatment and cure of spinal muscular atrophy (SMA), recently provided an additional $445,000 grant toward a gene therapy for SMA at Nationwide Children’s Hospital.
12366896
By Mary Ann Liebert, Inc., publishers
Contact: Kathryn Ryan, Mary Ann Liebert, Inc., (914) 740-2100, kryan@liebertpub.com Pioneer Award Recipients Robin Ali, PhD, Jean Bennett, MD, PhD, and William Hauswirth, PhD Honored for Their Research on Gene Therapy in Eye Disorders New Rochelle,...
12349466
By Mary Ann Liebert, Inc., publishers
Contact: Kathryn Ruehle, Mary Ann Liebert, Inc, (914) 740-2100, kruehle@liebertpub.com Splice-Switching Oligonucleotide Therapeutics Is Promising New Method for Editing Gene Transcripts New Rochelle, NY—In splice-switching, an innovative therapeutic...
12340580
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com Frederic Bushman, PhD Receives Pioneer Award for Advancing Therapeutic Gene Delivery Methods New Rochelle, NY—Frederic D.
12317188
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com James Wilson, MD, PhD Receives Pioneer Award for Research on Gene Therapy and AAV Gene Delivery Systems New Rochelle, NY—James M.
12299634
By Mary Ann Liebert, Inc., publishers
Marina Cavazzana, MD, PhD, Paris Descartes University, and Adrian J. Thrasher, MD, PhD, University College London Institute of Child Health, have been honored with the Pioneer Award for basic and clinical gene therapy for immunodeficiency disorders.
12276341
By Mary Ann Liebert, Inc., publishers
for Developing First In Vivo Adenoviral Gene Delivery Vector
12264977
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.
12254276
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.

All Press Releases

By Mary Ann Liebert, Inc., publishers
Researchers used gene transfer to block the expression of one of the two main enzymes that break down alcohol in the liver, leading to the accumulation in liver cells of acetaldehyde, a metabolic byproduct of ethanol.
12654663
By Project Alive
Parents Trying to Help Fund a Cure For the Rare Disease Hunter Syndrome / MPS II
12648948
By Project Alive
Parent Efforts Bringing Awareness to the Rare Disease Hunter Syndrome / MPS II
12641592
By Aldevron
Henry Hebel has been named Chief Operating Officer of Aldevron, a leading global provider of contract plasmid DNA manufacturing, protein production and antibody discovery services.
By Boston Biotech Meetup
Join the Boston Biotech Meetup for Advances in Gene Therapy, an evening of networking, presentations and discussion with local scientists.
By Mary Ann Liebert, Inc., publishers
Researchers are beginning to gain a clearer understanding of how the immune system responds, in both a reactive and tolerant way, to gene therapy delivered using what has become the preferred gene delivery vector, adeno-associated viruses (AAV).
By Partners4Access
Partners4Access Managing Partner Sophie Schmitz attended the World Orphan Drug Congress in Washington and reports insights from the Glybera case.
By Mary Ann Liebert, Inc., publishers
A new study examined 42 combinations of promoters and enhancers for human factor VIII (hFVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector constructs to take forward into development.
By Mary Ann Liebert, Inc., publishers
Overwhelming evidence from the biomedical literature shows that adeno-associated virus 2 (AAV2), a viral vector often used to deliver therapeutic genes, is not associated with cancer and, in fact, may protect against cancer.
12619832
By FAST
A pioneer on the frontier of genetic medicine and his team at one of the nation's top-five medical research schools have joined forces with FAST (Foundation for Angelman Syndrome Therapeutics) to develop a treatment for the rare disorder Angelman...
12597830
By Saving Case & Friends, Inc.
Parent-led fundraising efforts have donated over $500,000 to treat the rare disease Hunter Syndrome (MPS II)
By Allied Market Research
A new report published by Allied Market Research titled, "Regenerative Medicine Market- Global Opportunity Analysis and Industry Forecast, 2014 - 2022", projects that the global regenerative medicine market would reach $30,237 million by 2022.
12588923
By MoBiTec GmbH
AUMsilence self-delivering oligos achieve highly efficient and potent antisense-based gene knockdown. No need to use toxic transfection reagents. Especially designed for primary cells and very difficult-to-transfect cell types.
12554233
By Saving Case & Friends, Inc.
Efforts Bringing Awareness to Hunter Syndrome Are Recognized by Telly Awards and International Songwriting Competition
12474216
By Project Alive, a campaign of Saving Case & Friends
Parents of children with the rare disease Hunter Syndrome launched a compelling awareness and fundraising campaign with celebrity support including Seattle Seahawks head coach Pete Carroll and radio host Dave Ramsey.
By Foundation Care Pharmacy
Foundation Care Pharmacy, located in Earth City, MO, will be one of the pharmacies to provide cystic fibrosis patients with the new Vertex drug ORKAMBI™ (lumacaftor/ivacaftor).
By Cure SMA
Cure SMA, the leading organization dedicated to the treatment and cure of spinal muscular atrophy (SMA), recently provided an additional $445,000 grant toward a gene therapy for SMA at Nationwide Children’s Hospital.
By SMi Group Ltd
SMi’s BioBanking conference will be taking place on the 22 - 23 June 2015 at the Holiday Inn Regents Park Hotel in London, UK.
By Delveinsight Business Research LLP
DelveInsight a Market Research & Business Consulting firm has started a promotional offer on its Gene therapy reports highlighting their on-going demand across the globe.
By Visiongain
Visiongain’s new report predicts the world stem cell technologies market will reach $7.2bn in 2014. The overall industry will earn $12bn in 2018, achieving high revenue growth from 2015 to 2025.
By MoBiTec GmbH
Experience the transfection breakthrough. Achieve superior transfections with an innovative polymeric system that efficiently delivers both DNA and RNA out of the endosome and into the cytoplasm overcoming a critical barrier to nucleic acid delivery.
By Delveinsight Business Research LLP
Take Advantage of the very lucrative gene therapy market and play in the rare-air of the very few with DelveInsight’s Gene Therapy Reports!
12366896
By Mary Ann Liebert, Inc., publishers
Contact: Kathryn Ryan, Mary Ann Liebert, Inc., (914) 740-2100, kryan@liebertpub.com Pioneer Award Recipients Robin Ali, PhD, Jean Bennett, MD, PhD, and William Hauswirth, PhD Honored for Their Research on Gene Therapy in Eye Disorders New Rochelle,...
12349466
By Mary Ann Liebert, Inc., publishers
Contact: Kathryn Ruehle, Mary Ann Liebert, Inc, (914) 740-2100, kruehle@liebertpub.com Splice-Switching Oligonucleotide Therapeutics Is Promising New Method for Editing Gene Transcripts New Rochelle, NY—In splice-switching, an innovative therapeutic...
12340580
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com Frederic Bushman, PhD Receives Pioneer Award for Advancing Therapeutic Gene Delivery Methods New Rochelle, NY—Frederic D.
12317188
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com James Wilson, MD, PhD Receives Pioneer Award for Research on Gene Therapy and AAV Gene Delivery Systems New Rochelle, NY—James M.
12299634
By Mary Ann Liebert, Inc., publishers
Marina Cavazzana, MD, PhD, Paris Descartes University, and Adrian J. Thrasher, MD, PhD, University College London Institute of Child Health, have been honored with the Pioneer Award for basic and clinical gene therapy for immunodeficiency disorders.
By Mary Ann Liebert, Inc., publishers
Contact: Jennifer Quigley, Mary Ann Liebert, Inc, (914) 740-2100, ext.
By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100 (914) 740-2100, ext. 2156, vcohn@liebertpub.com Joseph Glorioso, PhD Receives Pioneer Award for Engineering Herpes Simplex Virus Gene Delivery Systems New Rochelle, NY—Joseph C.
12276341
By Mary Ann Liebert, Inc., publishers
for Developing First In Vivo Adenoviral Gene Delivery Vector

Page:
Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share